



HAL
open science

Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines

Carlo Pifferi, Baptiste Thomas, David Goyard, Nathalie Berthet, Olivier Renaudet

► **To cite this version:**

Carlo Pifferi, Baptiste Thomas, David Goyard, Nathalie Berthet, Olivier Renaudet. Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines. *Chemistry - A European Journal*, 2017, 23 (64), pp.16283-16296. 10.1002/chem.201702708 . hal-03323891

HAL Id: hal-03323891

<https://hal.science/hal-03323891v1>

Submitted on 23 Aug 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Anticancer Agents

Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines

Carlo Pifferi,^[a] Baptiste Thomas,^[a] David Goyard,^[a] Nathalie Berthet,^[a] and Olivier Renaudet*^[a, b]

Abstract: The large majority of TACA-based (TACA = Tumor-Associated Carbohydrate Antigens) antitumor vaccines target only one carbohydrate antigen, thereby often resulting in the incomplete destruction of cancer cells. However, the morphological heterogeneity of the tumor glycocalix, which is in constant evolution during malignant transformation, is a crucial point to consider in the design of vaccine candidates. In this paper, an efficient synthetic strategy based on orthogonal chemoselective ligations to prepare fully synthetic glycosylated cyclopeptide scaffolds grafted

with both Tn and TF antigen analogues is reported. To evaluate their ability to be recognized as tumor antigens, direct interaction ELISA assays have been performed with the anti-Tn monoclonal antibody 9A7. Although both heterovalent structures showed binding capacities with 9A7, the presence of the second TF epitope did not interfere with the recognition of Tn except in one epitope arrangement. This heterovalent glycosylated structure thus represents an attractive epitope carrier to be further functionalized with T-cell peptide epitopes.

Introduction

Carbohydrate-based vaccines have recently emerged as a promising approach in cancer immunotherapy. This major achievement is the result of decades of efforts during which immunologists, glyco-biologists, and chemists have joined forces to design synthetic or semi-synthetic structures to selectively eradicate malignant cells by the immune system.^[1–5] The identification of aberrant glycosylation patterns at the surface of cancer cells, namely TACAs (Tumor-Associated Carbohydrate Antigens), which discriminate healthy and malignant tissues is indisputably the source of inspiration in this field.^[6–9] The over-expression of these antigens as membrane glycoproteins or glycolipids has consequences in signal transduction and tumor cell metastasis^[10,11] and often correlates to poor prognosis.^[12,13] Although a small minority of cancer patients has shown a natural production of anti-TACA antibodies, these glycans are rarely capable of inducing a robust immune response due to their intrinsic nature.^[14] As a matter of fact, some TACAs are also expressed at low levels in normal tissues, making them to be perceived as “self-antigens” by the human immune system.^[15] Moreover, the nature of immune response against

TACAs lacks the sustain of activated T-helper cells, which promotes the proliferation and differentiation of B-cells, leading to the production of high-affinity IgG antibodies.^[16] To induce such a T-cell-dependent response, the design of carbohydrate-based vaccines requires protein or peptide carriers containing known T-cell epitopes.^[17–20] Alternatively, a toll-like receptor (TLR) ligand can be included in the vaccine formulation to promote antigen-presenting cells (APC) maturation and subsequent cytokine release to enhance the potency of the antigen-specific immune response.^[21]

Over the last years, many advances have contributed to the development of TACA-based conjugate vaccines.^[22–25] First, the development of powerful chemical synthesis of oligosaccharides and chemoenzymatic strategies allowed for minimized batch-to-batch variations due to the heterogeneity of extracted glycans, to obtain higher quality carbohydrate epitopes.^[26–28] Secondly, it was clearly established that TACAs should preferentially be presented in a multivalent display to mimic the native structures expressed on tumors and promote the efficient delivery of the vaccine prototype to B-cells by virtue of cell receptor cross-linking and endocytosis.^[29–31] In addition, unnatural TACAs can be introduced in conjugated vaccines to increase their resistance towards endogenous glycosylhydrolases and the immunogenicity of the constructs.^[32,33] In other studies, protein carriers^[34,35] have been replaced with well-defined, fully synthetic and non-immunogenic scaffolds featuring clustered carbohydrate epitopes and immuno-stimulant peptide sequences.^[36] The development of less toxic adjuvants and self-adjuvanting multi-component vaccines has also been investigated, resulting in remarkable immunological effects.^[37–45] Finally, when many structures only present the carbohydrate moiety of the TACA instead of the native glycopep-

[a] C. Pifferi, Dr. B. Thomas, Dr. D. Goyard, Dr. N. Berthet, Prof. Dr. O. Renaudet
Univ. Grenoble Alpes, CNRS, DCM UMR 5250
38000 Grenoble (France)
E-mail: olivier.renaudet@univ-grenoble-alpes.fr

[b] Prof. Dr. O. Renaudet
Institut Universitaire de France
103 boulevard Saint-Michel, 75005 Paris (France)

Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under <https://doi.org/10.1002/chem.201702708>.

tide antigen, more relevant results have been obtained compared to when the TACA are linked to an amino acid of the native peptide fragment.^[30,46–48] However, despite these important improvements, no carbohydrate-based antitumor synthetic vaccine has succeeded in clinical trials.^[49]

One critical but underestimated aspect in the design of antitumoral vaccines is the morphological heterogeneity of the tumor glycocalyx, which is in constant evolution during malignant transformation.^[50–54] The large majority of vaccines target only one carbohydrate antigen expressed on tumors, which results in the incomplete destruction of cancer cells and neglect a compelling population of transformed cells. Therefore, it appears essential to consider the heterogeneous expression of TACAs to activate different population of B-cells and thus stimulate a multi-faceted response against a large population of tumors present at different stage of the disease.^[55] Following this idea, the first semi-synthetic vaccine candidates combining multiple TACAs have been pioneered by the Danishefsky group.^[56] It was demonstrated that when the highly immunogenic Keyhole Limpeth Hemocyanin (KLH) protein carrier is functionalized with different TACAs (i.e., Globo-H, Le^x, and Tn antigens), a similar antibody response was generated in murine models compared with co-administration of the individual monomers. More interestingly, the antibodies raised against the multi-antigenic construct showed equal or higher reactivity towards human cell lines expressing native antigen forms. The same group further extended this approach with an unimolecular pentavalent construct featuring Globo-H, STn, Tn, GM2, and TF antigens (Figure 1 A).^[57] This second-generation vaccine showed promising preclinical results, being capable of producing excellent IgG and IgM antibody titers against all five antigens in mice models, when administered in the presence of QS-21 adjuvant. This vaccine prototype is currently under phase I clinical trial against ovarian cancer. Although this approach opens promising perspectives in immunotherapy and was recently used only in semi-synthetic glycoprotein/glycolipid-based approaches,^[30,58] no fully synthetic vaccine prototype

displaying different associations of TACAs have been described so far.

Herein, we report an efficient synthetic strategy based on orthogonal chemoselective ligations to prepare vaccine candidates combining several carbohydrate antigens. For this purpose, we focused our attention on the preparation of glycosylated cyclopeptide scaffolds grafted with both Tn and TF antigen analogues, and dedicated to be further functionalized with T-cell peptide epitopes (Figure 1 B).^[33,41,59–62] We next evaluated through direct interaction ELISA assays the ability of our multivalent glycoclusters to interact with monoclonal anti-Tn antibody to assess whether the presence of a second epitope (i.e., TF) could interfere with the specific recognition of the Tn moiety.

Results and Discussion

The development of efficient methodologies to prepare heterovalent glycostructures represents not only a synthetic challenge, but also an important progress to deepen the influence of glycoheterogeneity in interaction between carbohydrates and antibodies or lectins.^[63,64] In the course of our recent studies in this field, we envisioned to build our multivalent Tn–TF-based heterovalent glycodendrimers, that is, compounds **1** and **2** (Figure 2), by using two orthogonal reactions: oxime ligation (OL) and copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC).^[65–67] Considering that our target molecules should contain carbohydrates in a separated (**1**) or shuffled (**2**) fashion, we have designed a divergent strategy that requires the synthesis of functionalized building blocks: i) Two “central” cyclopeptidic cores containing two aminoxy groups and two serine residues (**3**) on the upper domain of the scaffold, or four aldehyde groups (**4**); ii) Three additional cyclopeptidic “arms” bearing one aminoxy group on the lower domain and four serine residues on the upper domain (**5**), one aldehyde and four azido groups (**6**), or one aminoxy, two serines and two




Figure 1. A) Unimolecular pentavalent construct by Danishefsky's group. B) Our multivalent Tn/TF-based glycocluster.





Figure 2. General divergent strategy for the synthesis of heteroglycoclusters 1 and 2.

azides (7); iii) Aminoxy-Tn (8) and propargyl-TF (9) modified antigens (Figure 2).

Synthesis of carbohydrate antigens

The aminoxy-Tn **8** has been prepared following the strategy reported by our group.^[68] The propargylated TF antigen **9** was synthesized as shown in Scheme 1. Reaction of 1,3,4,6-tetra-*O*-acetyl-2-azido-2-deoxy- β -D-galactopyranose **10**^[54] with propargyl alcohol yielded compound **11**^[69] as an inseparable anomeric mixture. Subsequent treatment with thioacetic acid in pyridine led to the desired 2-acetamido derivative **12**.^[70] Separation of the anomers could be achieved at this stage and compound **12** was then deacetylated and selectively protected on positions 4 and 6 to give the glycosyl acceptor **13**. Trimethylsilyl trifluoromethanesulfonate-promoted glycosylation with trichloroacetimidate **14** yielded disaccharide **15** that was fully deprotected to afford propargyl-TF **9**.




Scheme 1. Synthesis of the propargylated TF antigen **9**. Reagents and conditions: [a] Propargyl alcohol, $\text{BF}_3 \cdot \text{Et}_2\text{O}$, CH_2Cl_2 , 40°C , 8 h, 85%; [b] AcSH , pyridine, r.t., overnight, 70%; [c] MeONa/MeOH (pH 10), r.t., 2 h, 95%; [d] PhC(OMe)_2 , camphorsulfonic acid (CSA), CH_3CN , r.t., 72 h, 92%; [e] Trimethylsilyl trifluoromethanesulfonate (TMSOTf), CH_2Cl_2 , -15°C , 30 min, 75%; [f] 70% $\text{AcOH/H}_2\text{O}$, 60°C , 4 h, 85%.

Synthesis of cyclopeptidic “cores” and “arms”

The synthesis of compounds **1** and **2** is based on a divergent modular approach in which a central scaffold (“core”) has first to be functionalized with four “arms”, and successively with modified TACAs. The first step of the synthetic route involved the solid phase peptide synthesis of the orthogonally protected sequence **A** on the Fmoc-Gly-SASRINTM resin (Fmoc = 9-fluorenylmethoxycarbonyl), in which we introduced the dipeptide building block **16**^[71] to reduce the number of steps in solution. After cleavage from the resin support in mild acidic conditions and cyclization in diluted $\text{DMF/CH}_2\text{Cl}_2$, compound **17** was obtained with an overall yield of 54%. Compound **17** underwent palladium-catalyzed deprotection of allyloxycarbonyl (Alloc) groups; the two resulting free amino groups in the upper domain were reacted with (Boc-aminoxy)acetic acid *N*-hydroxysuccinimide ester^[72] to afford fully protected intermediate **18**. The core scaffold **3** was obtained after treatment of **18** with TFA in the presence of a mixture of triisopropylsilane (TIS), water and hydroxylamine as scavengers (Scheme 2). The key intermediate **3** shows: (i) Two aminoxy groups, prone to react under oxime ligation conditions; (ii) Two serine residues as masked α -oxo aldehyde residues; and (iii) A free amino group on the lysine side-chain, on the lower domain.^[73]

The synthesis of the “right arm” **6** was performed starting from the synthesis of the sequence **B**, where 6-azido-*N*-Fmoc-norleucine **19**^[74] has been included. Cleavage from the resin and subsequent cyclization gave compound **20** with a 48% overall yield. Removal of acid-labile protecting groups of compound **20** afforded intermediate **21**, presenting four azido groups on the upper domain and a serine residue in



Scheme 2. Synthesis of “core” cyclopeptide **3**. Reagents and conditions: [a] 1% TFA/ CH_2Cl_2 , 10×10 min.; [b] PyBOP[®] (1.2 equiv), DIPEA (2.0 equiv), DMF/ CH_2Cl_2 (1:1), 0.5 mM linear peptide, r.t., 30 min, 54% overall; [c] Pd(PPh₃)₄ (0.3 equiv), PhSiH₃ (25 equiv), dry DMF/ CH_2Cl_2 (1:1), r.t., 30 min; [d] (Boc-aminooxy)acetic acid *N*-hydroxysuccinimide ester (1.2 equiv), DIPEA (1.5 equiv), dry DMF, r.t., 20 min, 72% over two steps; [e] 94% TFA, 2% TIS, 2% H₂O, 2% NH₂OH, r.t., 3 h, 93%.

the lower domain. This last residue was treated with sodium periodate to give the α -oxo aldehyde-containing intermediate **6**. In order to prevent the formation of undesired over-oxidation side products, the reaction was stopped by RP-HPLC purification after 40 minutes of reaction (Scheme 3).


Synthesis of cyclopeptidic “arms” of scaffold **2** started with compound **22**, featuring two protected serine residues, two azido residues, and one amino residue protected with 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl (Dde) group in the lower domain, which was obtained from the solid phase peptide synthesis of sequence C. Cleavage from the resin in mild acidic conditions, followed by cyclization afforded the desired compound with an overall yield of 55%. Deprotection of Dde

by means of a 2% solution of hydrazine monohydrate in *N,N*-Dimethylformamide (DMF) afforded compound **23**, the free amino group was functionalized with (Boc-Aminooxy)acetic acid *N*-hydroxysuccinimide ester and the resulting crude treated with a strong acidic deprotection cocktail to simultaneously cleave Boc and *tert*-butyl groups (Scheme 4). “Cyclopeptide arm” **7** was obtained in good yields (44% overall) after RP-HPLC purification.


Molecular assembly of the dendritic cores by OL

Conjugation between central scaffold **3** and “right arm” **6** was carried out via oxime ligation, in the presence of a 0.1% TFA solution in H₂O/ CH_3CN (1:1, pH 2.2) at 37 °C for 30 minutes, to afford compound **24** in excellent yield (75%) and purity. Oxidative cleavage of serine residues of compound **24** by treatment with sodium periodate gave compound **25**, which subsequently underwent oxime ligation with the “left arm” **5**^[60] to afford **26** in good yields (60% over two steps). Compound **27** was obtained upon treatment of **26** with sodium periodate and subsequent direct purification by HPLC (Scheme 5). The resulting multivalent scaffold **27**, featuring eight α -oxo aldehyde and eight azido functionalities displayed in separated “arms”, was thus ready for the final conjugation step, featuring saccharide epitopes **8** and **9**, respectively through both oxime ligation and copper(I)-catalyzed azide-alkyne cycloaddition.


For the synthesis of the “shuffled” heteroglycocluster **2**, we envisaged a divergent strategy employing the “core” scaffold **4**^[75] displaying four α -oxo aldehyde groups. This central unit was reacted with 6 equivalents of aminooxy-containing “cyclopeptide arm” **7** under oxime ligation conditions to give com-



Scheme 3. Synthesis of “right arm” cyclopeptide **6**. Reagents and conditions: [a] 1% TFA/ CH_2Cl_2 , 10×10 min; [b] PyBOP[®] (1.2 equiv), DIPEA (2.0 equiv), DMF/ CH_2Cl_2 (1:1), 0.5 mM linear peptide, r.t., 30 min, 48% overall; [c] 96% TFA, 2% TIS, 2% H₂O, r.t., 3 h, 96%; [d] NaIO₄ (10 equiv), H₂O, r.t., 40 min, 71%.



Scheme 4. Synthesis of "arm" cyclopeptide **7**. Reagents and conditions: [a] 1% TFA/ CH_2Cl_2 , 10×10 min; [b] PyBOP[®] (1.2 equiv), DIPEA (2.0 equiv), DMF/ CH_2Cl_2 (1:1), 0.5 mM linear peptide, r.t., 30 min, 55% overall; [c] 2% N_2H_4 /DMF, r.t., 20 min., 94%; [d] (Boc-aminoxy)acetic acid *N*-hydroxysuccinimide ester (1.2 equiv), DIPEA (1.5 equiv), dry DMF, r.t., 20 min; [e] 94% TFA, 2% TIS, 2% H_2O , 2% NH_2OH , r.t., 3 h, 86% over two steps.




Scheme 5. Synthesis of multivalent scaffold **27**. Reagents and conditions: [a] 0.1% TFA in $\text{H}_2\text{O}/\text{CH}_3\text{CN}$ (1:1), 37°C , 30 min, 75%; [b] NaIO_4 (20 equiv), H_2O , r.t., 40 min, 70%; [c] 0.1% TFA in $\text{H}_2\text{O}/\text{CH}_3\text{CN}$ (1:1), 37°C , 30 min, 85%; [d] NaIO_4 (80 equiv), H_2O , r.t., 40 min, 78%.

pound **28**. The subsequent oxidative cleavage of serine residues afforded the desired compound **29** in good yields (68% over two steps). (Scheme 6)

Functionalization of the dendrimers with TACAs by OL and CuAAC

With multivalent scaffolds **27** and **29** in hand, we proceeded with a sequential one-pot strategy in which the first coupling involved the oxime ligation between aminoxy-Tn **8** and the


eight aldehyde residues displayed on the multivalent scaffolds. As described above, reaction conditions involved 1.5 equivalents of aminoxy-saccharide per aldehyde, in a water/acetonitrile mixture containing 0.1% of TFA. The reaction mixture was incubated at 37°C and after 30 minutes LC-MS analysis showed complete conversion in the octa-Tn intermediate. Phosphate buffer solution (PBS, pH 7.4, 10 mM) was added to the reaction mixture in order to adjust the pH, then propargyl-TF **9** was added to the crude, along with CuSO_4 , tris(3-hydroxypropyl)triethylammonium (THPTA) and sodium ascorbate



Scheme 6. Synthesis of multivalent scaffold **29**. Reagents and conditions: [a] 0.1% TFA/H₂O, 37 °C, 30 min, 87%; [b] NaIO₄ (80 equiv), H₂O, r.t., 40 min, 78%.

(Scheme 7),^[76] RP-UPLC-MS analysis showed complete conversion after 1.5 hours reaction at room temperature (See the Supporting Information for chromatographic and ESI⁺ data).

Despite the structural complexity of these compounds, in addition to classic mass spectrometry and analytical chromatography, we have confirmed the correct functionalization of



Scheme 7. Synthesis of compounds **1** and **2**. Reagents and conditions: [a] 0.1% TFA in H₂O/CH₃CN, 37 °C, 30 min; [b] CuSO₄ (1.5 equiv), Na ascorbate (15 equiv), THPTA (8 equiv), PBS (pH 7.4, 10 mM), r.t., 90 min.

heteroglycoclusters **1** and **2** by $^1\text{H-NMR}$. Characteristic signals for anomeric protons of Tn (≈ 5.6 ppm) and TF (≈ 5.0 ppm), oxime protons (≈ 7.8 ppm) and 1,4-triazole protons (≈ 8.0 ppm) have been detected and integrated to show the expected ratio (Figure 3).

ELISA direct interaction assays

Before undertaking immunological assays in mice, we decided to evaluate first the ability of our multivalent glycosylated scaffolds to interact with monoclonal anti-Tn antibody. This represents an essential step to validate before going further in the synthesis of antitumor vaccines. Firstly because an efficient recognition of membrane-bound antibodies is a prerequisite for the stimulation of B-cells,^[77] and secondly because the presence of the TF epitope could interfere with the specific recognition of the Tn moiety. To perform this binding study with the heteroclusters **1** and **2**, we have synthesized the hexadecavalent homocluster **30** (p. S29, Supporting Information), featuring sixteen copies of Tn antigen, the tetravalent homoclusters **32** and **33** (pp. S35 and S37, Supporting Information), grafted with *N*-acetyl glucosamine, and the tetravalent heterocluster **31** (p. S32, Supporting Information), that will be used as controls (Figure 4 A).

We have selected the monoclonal antibody 9A7, which has been shown to have good to excellent ability to recognize Tn-positive human cancer cells such as MCF-7, LS174T, and Jurkat.^[78] Each molecule have been coated at different concentrations into microtiter wells and their ability to be recognized by the anti-Tn MAb (9A7) was studied. Compound concentration giving the same absorbance value at 490 nm was used as the indicator of the recognition ability by 9A7 (Figure 4B). Although the best interaction was observed for the hexadecavalent homoglycocluster **30**, hexadecavalent heteroglycoclusters **1** and **2** were both recognized by the anti-Tn mAb, keeping in mind that **30** displays a 2-fold increased Tn ratio compared to **1** and **2**. More interesting was the high sensitivity of the anti-Tn mAb to the epitope presentation. A significant difference was observed in the mAb recognition of **1** and **2** varying only by the TF and Tn epitopes distribution on the scaffold. Compound **1** showed a lower efficiency than **30**, presumably because the number of Tn antigens (i.e., eight) is half lower than in the most active compound **30** (i.e., sixteen). By contrast, compound **2** which displays a similar number of Tn than **1** was found to be less efficient. These results clearly indicate that the TF epitope interfere with the Tn recognition by 9A7 only in compound **2**. These results could be alternatively interpreted as a consequence of the differences in the spatial distribution and interspace distances between the Tn antigens in compounds **1** and **2**. Although, the tetravalent heteroglycocluster **31** failed to show a significant interaction with 9A7, suggesting that only two copies of Tn is not sufficient for an efficient recognition. As expected, the tetravalent homoclusters **32** and **33** used as negative control did not show any signal, thus confirming the absence of unspecific interactions between 9A7 and similar carbohydrates, and/or the peptide scaffold itself.

Conclusion

To conclude, we report the first full synthesis of glycosylated scaffolds as carriers of cancer-related antigens for vaccine design. By using OL and CuAAC ligations, we have prepared two hexadecavalent glycodendrimers with high yield and purity grafted with both Tn and TF antigen analogues in different topological arrangement. To evaluate their ability to be recognized as tumor antigens, direct interaction ELISA assays have been performed with the anti-Tn monoclonal antibody 9A7. This study has highlighted that either the presence of the second TF epitope or the epitope distribution itself interfere with the recognition of Tn in compound **2** whereas no significant decrease of binding has been observed for compound **1**. Considering that an efficient recognition by B-cell antigen receptor (i.e., membrane-bound antibody) is crucial for activation of the immune system,^[76] the identification of this heterovalent glycosylated structure represents a key step toward the design of synthetic vaccines. This epitope carrier will be functionalized with T-cell peptide epitopes following a procedure described recently in our group.^[33] Results of immunological evaluation of the derived antitumoral vaccine candidate will be reported in a near future.

Experimental Section

General procedures

All chemical reagents were purchased from Aldrich (Saint Quentin Fallavier, France) or Acros (Noisy-Le-Grand, France). All protected amino acids and Fmoc-Gly-Sasrin[®] resin were obtained from Advanced ChemTech Europe (Brussels, Belgium). For peptides and glycopeptides, analytical RP-HPLC was performed on a Waters system equipped with a Waters 2695 separations module and a Waters 2487 Dual Absorbance UV/Vis Detector. Analytical RP-HPLC was carried out at 1.23 mL min^{-1} (Interchim UPTISPHERE X-SERIE, C_{18} , $5\ \mu\text{m}$, $125\times 3.0\text{ mm}$) with UV monitoring at 214 nm by using a linear A–B gradient (buffer A: 0.09% $\text{CF}_3\text{CO}_2\text{H}$ in water; buffer B: 0.09% $\text{CF}_3\text{CO}_2\text{H}$ in 90% acetonitrile). Purifications were carried out at 22.0 mL min^{-1} (VP $250\times 21\text{ mm}$ nucleosil 100-7 C_{18}) with UV monitoring at 214 and 250 nm by using a linear A–B gradient. Analytical RP-UPLC was carried out at 0.6 mL min^{-1} (Phenomenex WIDEPOR XB- C_{18} , $3.6\ \mu\text{m}$, $50\times 2.1\text{ mm}$) with UV monitoring at 214 nm by using a linear C–D gradient (buffer C: 0.1% CH_2O_2 in water; buffer D: 0.1% CH_2O_2 in acetonitrile). For carbohydrate derivatives, moisture-sensitive reactions were performed under an argon atmosphere by using oven-dried glassware and reactions was monitored by using TLC with silica gel 60 F254 precoated plates (Merck). Spots were inspected by UV light and visualized by charring with 10% H_2SO_4 in EtOH for carbohydrates. Silica gel 60 (0.063–0.2 mm or 70–230 mesh, Merck) was used for column chromatography. ^1H and ^{13}C NMR spectra were recorded on Bruker Avance 400 MHz or Bruker Avance III 500 MHz spectrometers and chemical shifts (δ) were reported in parts per million (ppm). Spectra were referenced to the residual proton solvent peaks relative to the signal of CDCl_3 ($\delta=7.26$ and 77.0 ppm for ^1H and ^{13}C) and D_2O (4.79 ppm for ^1H), assignments were performed by using GCOSY and GHMQC experiments. Standard abbreviations s, d, t, dd, br s, m refer to singlet, doublet, triplet, doublet of doublets, broad singlet, multiplet, respectively. The anomeric configuration was estab-




Figure 3. A) ^1H NMR (D_2O , 400 MHz) zoom of **1**; B) ^1H NMR (D_2O , 400 MHz) zoom of **2**; C) ESI^+ -MS spectrum of **1**; D) ESI^+ -MS spectrum of **2**; E) Analytical RP-HPLC profile of **1**; F) Analytical RP-HPLC profile of **2**.





Figure 4. A) Compounds tested in ELISA assay; B) Interaction curves of the monoclonal antibody Anti-Tn 9A7 with the glycoconjugates 30 (■), 1 (△), 2 (□), 31 (○), 32 (×), 33 (▲).

lished from $J_{1,2}$ coupling constants. HRMS and ESI-MS spectra of peptides and glycopeptides were measured on an Esquire 3000 spectrometer from Bruker or on an Acquity UPLC/MS system from Waters equipped with an SQ Detector 2. Bovine Serum Albumin (BSA), SIGMA FAST *O*-phenylenediamine dihydrochloride (OPD), 96-well microtiter Nunc-Immuno plates (Maxi-Sorp) and goat anti-Mouse IgG-HRP-linked antibody were purchased from Sigma-Aldrich. Monoclonal antibody anti-Tn (9A7) was kindly given by Prof. R. Lo-Man (Institut Pasteur, Paris, France). The microtiter plate reader was a POLARstar Omega (BMG LABTECH).

Procedure for solid-phase peptide synthesis

Assembly of protected linear peptide was performed manually or automatically (Syro II, Biotage) by employing solid-phase peptide synthesis (SPPS) protocol using the Fmoc/*t*Bu strategy and the

Fmoc-Gly-Sasrin® resin (loading = 0.7 mmol g^{-1}). Coupling reactions were performed using, relative to the resin loading, 1.5–2 equiv of *N*-Fmoc-protected amino acid in situ activated with PyBOP (1.5–2 equiv) and *N,N*-diisopropylethylamine (DIPEA, 3–4 equiv) in DMF (10 mL g^{-1} resin) for 30 min. Coupling reaction was checked by 2,4,6-Trinitrobenzenesulfonic Acid (TNBS) test using a solution of 1% trinitrobenzenesulfonic acid in DMF. *N*-Fmoc protecting groups were removed by treatment with piperidine/DMF (1:4, 10 mL g^{-1} resin) for 10 min. The process was repeated three times and the resin was further washed five times with DMF (10 mL g^{-1} resin) for 1 min. The peptide was released from the resin by treating 10 times with a cleavage solution of TFA: CH_2Cl_2 (1:99). The combined cleavage fractions were concentrated under reduced pressure, ice-cold Et_2O was added to induce precipitation and the linear peptide was obtained as a white powder after filtration and used without any further purification.

Procedure for peptide cyclization

All linear peptides were dissolved in CH₂Cl₂ (0.45–0.50 mM) and the pH of the solution was adjusted to 9 by addition of DIPEA. PyBOP (1.2 equiv) was added and the reaction mixture was stirred at room temperature for 30 minutes. The solvent was removed under reduced pressure and precipitation from diethyl ether afforded desired cyclic peptides as white solids.

Compound 1

To a solution of **27** (10.2 mg, 1.6 μmol) in a H₂O/CH₃CN (1:1, 1.0 mL) mixture containing 0.09% CF₃CO₂H, **8** (4.6 mg, 19.5 μmol) was added and the reaction heated at 37 °C without stirring. After 30 minutes, RP-UPLC showed complete conversion to the octa-Tn derivative: *t*_R = 2.37 min. (5–60% solv.D in 3.0 min.) (Figure S1). ESI⁺-MS *m/z* (Average MW) Elemental analysis calcd (%) for C₃₃₁H₅₃₀N₁₁₁O₁₁₈ [M+5H]⁵⁺: 1590.5, found: 1590.2; calcd for C₃₃₁H₅₂₉N₁₁₁O₁₁₈ [M+4H]⁴⁺: 1987.9, found: 1987.7.

To this mixture, **9** (8.3 mg, 19.7 μmol) was added, then 1.0 mL of PBS buffer (pH 7.4, 10 mM) was added and the solution degassed by argon bubbling for 15 minutes. A separate solution, containing CuSO₄ (0.5 mg, 2.0 μmol), THPTA (5.7 mg, 13.1 μmol) and sodium ascorbate (10.4 mg, 23.9 μmol) in previously degassed PBS buffer (1.0 mL, pH 7.4, 10 mM) was added to the reaction mixture. After 90 minutes stirring at room temperature, RP-UPLC showed complete conversion to compound **1**: *t*_R = 1.40 min. (5–60% solv.D in 3.0 min.) (Figure S3). ESI⁺-MS *m/z* (Average MW) Elemental analysis calcd (%) for C₄₆₇H₇₄₇N₁₁₉O₂₀₆ [M+6H]⁶⁺: 1887.4, found: 1887.4.

Chelex[®] resin was added to the reaction mixture and stirred for 30 minutes at room temperature in order to remove residues of copper. The crude was then purified by preparative RP-HPLC and lyophilized to afford 10.2 mg of pure **1** (55% yield). Analytical RP-HPLC: *t*_R = 7.54 min. (0–40% solv.B in 15 min.).

Compound 2

Compound **2** was obtained in 60% yield (10.0 mg) by following the same procedure reported above, starting from 9.2 mg (1.5 μmol) of compound **29** (see the Supporting Information). ESI⁺-MS *m/z* (Average MW) Elemental analysis calcd (%) for C₄₆₇H₇₄₇N₁₁₉O₂₀₆ [M+6H]⁶⁺: 1887.4, found: 1887.5. Analytical RP-HPLC: *t*_R = 7.60 min. (0–40% solv. B in 15 min.).

Compound 3

A solution containing trifluoroacetic acid (TFA), triisopropylsilane (TIS), water and hydroxylamine (2.0 mL, 94:2:2:2) was added to **18** (22.1 mg, 11.3 μmol) and the mixture stirred at room temperature for 3 hours. After addition of ice-cold Et₂O (10 mL) and filtration of the precipitate, the crude product was purified via preparative RP-HPLC to give, after lyophilization, compound **3** (14.1 mg) in 93% yield. ESI⁺-MS *m/z* (Monoisotopic MW) Elemental analysis calcd (%) for C₅₇H₁₀₂N₁₉O₁₈ [M+H]⁺: 1340.8, found: 1340.4; Elemental analysis calcd (%) for C₅₇H₁₀₃N₁₉O₁₈ [M+2H]²⁺: 670.9, found: 670.5; C₅₇H₁₀₇N₁₉O₁₈ Na₃ [M+6H+3Na]⁹⁺: 157.2, found: 157.0. Analytical RP-HPLC: *t*_R = 4.00 min. (0–30% solv. B in 15 min.).

Compound 6

To a solution of **21** (50.7 mg, 41.9 μmol) in H₂O (2.0 mL), sodium periodate (89.6 mg, 419 μmol) was added and the reaction mixture stirred at room temperature for 30 minutes. Direct RP-HPLC purification, followed by lyophilization afforded compound **6** (35.1 mg)

in 71% yield. HRMS (ESI⁺-TOF) *m/z* (Monoisotopic MW) Elemental analysis calcd (%) for C₄₉H₇₈N₂₃O₁₂ [M+H]⁺: 1180.6200, found: 1180.6211; Elemental analysis calcd (%) for C₄₉H₇₉N₂₃O₁₃Na [M+H₂O+Na]⁺: 1220.6125, found: 1220.6138. Analytical RP-HPLC: *t*_R = 6.78 min. (5–100% solv.B in 15 min.).

Compound 7

To a solution of anhydrous DMF (5 mL) containing DIPEA (13 μL, 74.6 μmol), compound **23** (69.4 mg, 44.5 μmol) and (Boc-Amino-oxo)acetic acid *N*-hydroxysuccinimide ester^[56] (14.1 mg, 48.9 μmol) were added. After 20 minutes stirring at room temperature the solvent mixture was concentrated under vacuum and ice-cold Et₂O was added to induce precipitation. The resulting yellowish precipitate was filtered, dried and used for the next step without any further purification. The crude product was added of a cocktail containing TFA, TIS, water and hydroxylamine (5.0 mL, 94:2:2:2) and the reaction stirred at room temperature for 3 hours. After addition of ice-cold Et₂O (30 mL) and filtration of the precipitate, the crude product was purified via preparative RP-HPLC to give, after lyophilization, compound **7** (50.5 mg) in 86% yield over two steps. HRMS (ESI⁺-TOF) *m/z* (Monoisotopic MW) Elemental analysis calcd (%) for C₅₅H₉₅N₂₂O₁₆ [M+H]⁺: 1319.7296, found: 1319.7302; Elemental analysis calcd (%) for C₅₅H₉₄N₂₂O₁₆Na [M+Na]⁺: 1341.7116, found: 1341.7123. Analytical RP-HPLC: *t*_R = 3.52 min. (5–100% solv. B in 15 min.).

Propargyl (β-D-galactopyranosyl)-(1-3)-2-acetamido-2-deoxy-α-D-galactopyranoside (9)

A solution of compound **15** (250 mg, 0.37 mmol) in 70% aqueous acetic acid (2.5 mL) was stirred at 60 °C for 4 hours. The mixture was concentrated under reduced pressure and co-evaporated with toluene. The residue was solubilized in dry methanol (5 mL) and a solution of sodium methoxide in methanol was added to reach approximately pH 9. The solution was stirred at room temperature overnight and neutralized with Amberlite IR-120 H⁺. The resin was filtered off, washed with methanol and the filtrate was concentrated under reduced pressure to afford the title compound after precipitation (MeOH/CH₂Cl₂) as a white amorphous solid (147 mg, 0.35 mmol, 95%); ¹H NMR (400 MHz, CD₃OD) δ = 5.02 (d, 1H, *J* = 3.7 Hz, H-1), 4.48 (dd, 1H, *J* = 3.7, 11.1 Hz, H-2), 4.40 (d, 1H, *J* = 7.6 Hz, H-1'), 4.31 (dd, 1H, *J* = 2.4, 15.9 Hz, CH₂CCH), 4.25 (dd, 1H, *J* = 2.4, 15.9 Hz, CH₂CCH), 4.17 (d, 1H, *J* = 2.2 Hz, H-4'), 3.91 (dd, 1H, *J* = 3.0, 11.1 Hz, H-3), 3.85 (t_{apr}, 1H, *J* = 6.0 Hz, H-5'), 3.81 (d, 1H, *J* = 2.9 Hz, H-4), 3.75 (dd, 2H, *J* = 6.9, 11.3 Hz, H-6a, H-6'a), 3.70 (dd, 2H, *J* = 5.1, 11.4 Hz, H-6b, H-6'b), 3.50–3.56 (m, 2H, H-2', H-5'), 3.44 (dd, 1H, *J* = 3.2, 9.7 Hz, H-3'), 2.85 (t, 1H, *J* = 2.3 Hz, CH₂CCH), 1.97 ppm (s, 3H, acetyl). Those data are in agreement with the literature.^[79]

Propargyl 2-acetamido-4,6-O-benzylidene-2-deoxy-α-D-galactopyranoside (13)

To a suspension of propargyl 2-acetamido-2-deoxy-α-D-galactopyranoside⁶⁴ (1.285 g, 4.95 mmol, 1 equiv) and benzaldehyde dimethyl acetal (1.116 mL, 7.43 mmol, 1.5 equiv) in dry acetonitrile was added camphorsulfonic acid (115 mg, 0.49 mmol, 0.1 equiv). The mixture was stirred at room temperature for 48 hours. The reaction was quenched with triethylamine (0.3 mL) and concentrated under reduced pressure. The crude mixture was purified over silica gel chromatography (CH₂Cl₂/MeOH 98:2) to afford the title compound as a white amorphous solid (1.550 g, 4.46 mmol, 90%); ¹H NMR (400 MHz, [D₆]acetone) δ = 7.54–7.56 (m, 2H, H-Ar), 7.32–7.39 (m, 3H, H-Ar), 6.95 (d, 1H, *J* = 7.8 Hz, NH), 5.65 (s, 1H, CHPh), 5.07 (d,

1H, $J=3.5$ Hz, H-1), 4.38 (td_{apr}, 1H, $J=8.6$, 3.5 Hz, H-2), 4.30 (d_{apr}, 1H, $J=3.4$ Hz, H-4), 4.29 (dd, 1H, $J=16.0$, 2.5 Hz, OCH₂CCH), 4.25 (dd, 1H, $J=16.0$, 2.5 Hz, OCH₂CCH), 4.17 (dd, 1H, $J=12.4$, 1.6 Hz, H-6a), 4.13 (dd, 1H, $J=12.5$, 1.7 Hz, H-6b), 3.88 (ddd, 1H, $J=11.1$, 9.2, 3.4 Hz, H-3), 3.79 (d_{apr}, 1H, $J=1.1$ Hz, H-5), 3.75 (d, 1H, $J=9.2$ Hz, OH-3), 2.97 (t, 1H, $J=2.4$ Hz, CH₂CCH), 1.91 ppm (s, 3H, acetyl); ¹³C NMR (100 MHz, [D₆]acetone) $\delta=170.9$ (C=O, acetyl), 139.9 (C-Ar), 129.4 (CH-Ar), 128.7 (2×CH-Ar), 127.3 (2×CH-Ar), 101.4 (CH-Ph), 98.3 (C-1), 80.3 (CH₂CCH), 76.9 (C-4), 76.1 (CH₂CCH), 69.8 (C-6), 68.2 (C-3), 64.4 (C-5), 55.4 (CH₂CCH), 51.1 (C-2), 22.9 ppm (CH₃, acetyl); HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) Elemental analysis calcd (%) for C₁₈H₂₂NO₆ [M+H]⁺: 348.1447, found: 348.1445.

Propargyl (2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)-(1-3)-2-acetamido-4,6-O-benzilidene-2-deoxy- α -D-galactopyranoside (15)

A solution of **13** (430 mg, 1.23 mmol, 1 equiv) and 2,3,4,6-tetra-O-acetyl- α -D-galactopyranosyl trichloroacetimidate (912 mg, 1.85 mmol, 1.5 equiv) in dry dichloromethane (10 mL) was stirred for 1 hour under argon at room temperature in the presence of activated 4 Å molecular sieve. trimethylsilyl trifluoromethanesulfonate (45 μ L, 0.25 mmol, 0.2 equiv) was added at -15°C and the reaction was stirred at -15°C for 30 minutes, quenched with triethylamine (50 μ L), filtered on a celite pad and concentrated under reduced pressure. The crude mixture was purified over silica gel chromatography (CH₂Cl₂/MeOH 98:2) to afford the title compound as a white amorphous solid (503 mg, 0.74 mmol, 60%). ¹H NMR (400 MHz, CDCl₃) $\delta=7.51$ – 7.54 (m, 2H, H-Ar), 7.32– 7.38 (m, 3H, H-Ar), 5.64 (d, 1H, $J=9.1$ Hz, NHAc), 5.54 (s, 1H, CH-Ph), 5.37 (d, 1H, $J=3.3$ Hz, H-4'), 5.18 (dd, 1H, $J=10.3$, 7.9 Hz, H-2'), 5.12 (d, 1H, $J=3.5$ Hz, H-1), 4.97 (dd, 1H, $J=10.3$, 3.5 Hz, H-3'), 4.75 (d, 1H, $J=7.9$ Hz, H-1'), 4.70 (ddd, 1H, $J=3.6$, 9.1, 11.4 Hz, H-2), 4.02– 4.30 (m, 7H, H-4, 2×H-6, 2×H-6', 2×CH₂CCH), 3.95 (dd, 1H, $J=3.2$, 11.2 Hz, H-3), 3.89 (t_{apr}, 1H, $J=5.9$ Hz, H-5'), 3.69 (t_{apr}, 1H, $J=10.3$ Hz, H-5), 2.46 (t, 1H, $J=2.4$ Hz, CH₂CCH), 2.14, 2.04, 2.03, 1.99, 1.96 ppm (5 s, 15H, 5×CH₃, acetyl); ¹³C NMR (125 MHz, CDCl₃) $\delta=170.7$, 170.6, 170.4, 170.3, 170.2 (5×C, acetyl), 128.5 (C-Ar), 128.3 (CH-Ar), 126.7 (2×CH-Ar), 126.6 (2×CH-Ar), 100.8 (C-1'), 97.0 (C-1), 78.6 (CH₂CCH), 75.4 (CH₂CCH), 72.7 (C-5'), 71.0 (C-3'), 70.9 (C-5), 69.0 (C-3), 68.6 (C-2'), 68.0 (C-4), 66.9 (C-4'), 62.6 (C-6), 61.3 (C-6'), 55.3 (CH₂CCH), 53.6 (C-2), 23.6, 20.9, 20.9, 20.8, 20.7 ppm (5×CH₃, acetyl); HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) Elemental analysis calcd (%) for C₃₂H₄₀NO₁₅ [M+H]⁺: 678.6577, found: 678.6570.

Compound 17

Starting from 200 mg of Fmoc-Gly-Sasrin[®] resin (loading = 0.7 mmol g⁻¹), linear sequence **A** was synthesized according to the procedure for solid-phase peptide synthesis and cleaved to its resin support to give the corresponding linear peptide. HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) calcd for C₈₄H₁₄₆N₁₇O₂₅ [M+H]⁺: 1794.0706, found: 1794.0641.

Following the procedure for peptide cyclization, cleaved sequence **A** gave compound **17** (134 mg) in 54% overall yield after RP-HPLC purification and lyophilization. HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) calcd for C₈₄H₁₄₄N₁₇O₂₄ [M+H]⁺: 1776.0600, found: 1776.0605; Elemental analysis calcd (%) for C₈₄H₁₄₃N₁₇O₂₄Na [M+Na]⁺: 1797.0390, 1797.0406. Analytical RP-HPLC: $t_R=9.62$ min. (5–100% solv. B in 15 min.).

Compound 18

To a solution of **17** (72.3 mg, 40.7 μ mol) in a mixture of anhydrous DMF/CH₂Cl₂ (1:1, 10 mL), phenylsilane (250 μ L, 2.0 mmol) and Pd(PPh₃)₄ (9.4 mg, 8.13 μ mol) were added and the reaction stirred at room temperature for 30 minutes. MeOH (5 mL) was added to the mixture and the reaction stirred until production of CO₂ ceased. The reaction mixture was concentrated under vacuum and ice-cold Et₂O (20 mL) was added to induce precipitation. The resulting yellowish precipitate was filtrated, dried, and used without any further purification for the subsequent step. To a solution of the crude mixture in anhydrous DMF (5 mL), DIPEA (22 μ L, 126 μ mol) and (Boc-Aminoxy)acetic acid *N*-hydroxysuccinimide ester^[71] (25.8 mg, 89.5 μ mol) were added. After 20 minutes stirring at room temperature, the reaction mixture was directly purified via preparative RP-HPLC and lyophilized to give compound **18** (57.2 mg) in 72% yield over two steps. HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) Elemental analysis calcd (%) for C₉₀H₁₅₇N₁₉O₂₈Na [M+Na]⁺: 1975.1343, found: 1975.1371. Analytical RP-HPLC: $t_R=9.72$ min. (5–100% solv. B in 15 min.).

Compound 20

Starting from 200 mg of Fmoc-Gly-Sasrin[®] resin (loading = 0.7 mmol g⁻¹), linear sequence **B** was synthesized according to the procedure for solid-phase peptide synthesis and cleaved to its resin support to give the corresponding linear peptide. HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) Elemental analysis calcd (%) for C₅₉H₁₀₁N₂₄O₁₅ [M+H]⁺: 1385.7878, found: 1385.7856.

Following the procedure for peptide cyclization, cleaved sequence **B** gave compound **20** (91.9 mg) in 48% overall yield after RP-HPLC purification and lyophilization. HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) Elemental analysis calcd (%) for C₅₉H₉₉N₂₄O₁₄ [M+H]⁺: 1367.7773, found: 1367.7745; Elemental analysis calcd (%) for C₅₉H₉₈N₂₄O₁₄Na [M+Na]⁺: 1389.7592, found: 1389.7561. Analytical RP-HPLC: $t_R=8.52$ min. (5–100% solv. B in 15 min.).

Compound 21

A solution containing trifluoroacetic acid (TFA), triisopropylsilane (TIS) and water (2.0 mL, 96:2:2) was added to **20** (78.5 mg, 57.4 μ mol). After 3 hours stirring at room temperature the reaction mixture was added to ice-cold Et₂O (10 mL) and the resulting precipitate was filtrated and dried. After RP-HPLC purification and lyophilization, compound **21** (64.7 mg) was obtained in 96% yield. HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) Elemental analysis calcd (%) for C₅₀H₈₃N₂₄O₁₂ [M+H]⁺: 1211.6622, found: 1211.6602. Analytical RP-HPLC: $t_R=6.59$ min. (5–100% solv. B in 15 min.).

Compound 22

Starting from 200 mg of Fmoc-Gly-Sasrin[®] resin (loading = 0.7 mmol g⁻¹), linear sequence **C** was synthesized according to the procedure for solid-phase peptide synthesis and cleaved to its resin support to give the corresponding linear peptide. HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) calcd for C₈₁H₁₃₈N₂₁O₂₁ [M+H]⁺: 1741.0376, found: 1741.0366; calcd for C₈₁H₁₃₇N₂₁O₂₁Na [M+Na]⁺: 1763.0196, found: 1763.0176. Following the procedure for peptide cyclization, cleaved sequence **C** gave compound **22** (132.7 mg) in 55% overall yield after RP-HPLC purification and lyophilization. HRMS (ESI⁺-TOF) m/z (Monoisotopic MW) calcd for C₈₁H₁₃₆N₂₁O₂₀ [M+H]⁺: 1724.0300, found: 1724.0282; Elemental analysis calcd (%) for C₈₁H₁₃₅N₂₁O₂₀Na [M+Na]⁺: 1745.0090, found: 1745.0078. Analytical RP-HPLC: $t_R=9.60$ min. (5–100% solv. B in 15 min.).

Compound 23

To a 2% solution of hydrazine monohydrate (5.0 mL), **22** (90.3 mg, 52.4 μmol) was added and the reaction stirred at room temperature for 20 minutes. The solvent mixture was concentrated under vacuum and directly purified via preparative RP-HPLC to give, after lyophilization, compound **23** (76.8 mg) in 94% yield. HRMS (ESI⁺-TOF) *m/z* (Monoisotopic MW) Elemental analysis calcd (%) for C₇₁H₁₂₄N₂₁O₁₈ [M+H]⁺: 1558.9433, found: 1558.9458. Analytical RP-HPLC: *t*_R = 8.65 min. (5–100% solv. B in 15 min.).

Compound 24

To a mixture of H₂O/CH₃CN (1:1, 1.0 mL) containing 0.09% CF₃CO₂H, **3** (12.1 mg, 9.0 μmol) and **6** (31.9 mg, 27.0 μmol) were added and the reaction mixture was heated at 37 °C for 30 minutes. RP-HPLC purification, followed by lyophilization, afforded pure compound **24** (24.7 mg) in 75% yield. ESI⁺-MS *m/z* (Average MW) Elemental analysis calcd (%) for C₁₅₅H₂₅₃N₆₅O₄₀ [M+2H]²⁺: 1833.5, found: 1833.5; calcd for C₁₅₅H₂₅₄N₆₅O₄₀ [M+3H]³⁺: 1222.7, found: 1222.6; Elemental analysis calcd (%) for C₁₅₅H₂₅₄N₆₅O₄₀ [M+3H+Na]⁴⁺: 922.8, found: 922.8. Analytical RP-HPLC: *t*_R = 8.17 min. (5–100% solv. B in 15 min.).

Compound 25

To a solution of **24** (22.3 mg, 6.1 μmol) in H₂O (2.0 mL), sodium periodate (26.1 mg, 122 μmol) was added and the reaction mixture stirred at room temperature for 30 minutes. Direct RP-HPLC purification, followed by lyophilization afforded compound **25** (16.5 mg) in 75% yield. ESI⁺-MS *m/z* (Average MW) Elemental analysis calcd (%) for C₁₅₃H₂₄₆N₆₃O₄₂Na [M+H₂O+H+Na]²⁺: 1831.5, found: 1831.5; Elemental analysis calcd (%) for C₁₅₃H₂₄₆N₆₃O₄₂Na₂ [M+H₂O+H+2Na]³⁺: 1228.7, found: 1228.6; Elemental analysis calcd (%) for C₁₅₃H₂₄₆N₆₃O₄₂Na₃ [M+H₂O+H+3Na]⁴⁺: 927.2, found: 927.2. Analytical RP-HPLC: *t*_R = 8.49 min. (5–100% solv. B in 15 min.).

Compound 26

To a mixture of H₂O/CH₃CN (1:1, 1.0 mL) containing 0.09% CF₃CO₂H, **25** (16.0 mg, 4.4 μmol) and **5**^[45] (19.0 mg, 13.2 μmol) were added and the reaction mixture was heated at 37 °C for 30 minutes. RP-HPLC purification, followed by lyophilization, afforded pure compound **26** (24.1 mg) in 85% yield. ESI⁺-MS *m/z* (Average MW) Elemental analysis calcd (%) for C₂₇₅H₄₅₇N₁₀₃O₇₈ [M+4H]⁴⁺: 1613.6, found: 1613.5; calcd for C₂₇₅H₄₅₈N₁₀₃O₇₈ [M+5H]⁵⁺: 1291.0, found: 1291.0; Elemental analysis calcd (%) for C₂₇₅H₄₅₉N₁₀₃O₇₈ [M+6H]⁶⁺: 1076.0, found: 1076.1; Elemental analysis calcd (%) for C₂₇₅H₄₆₀N₁₀₃O₇₈ [M+7H]⁷⁺: 922.5, found: 922.5. Analytical RP-HPLC: *t*_R = 7.23 min. (5–100% solv. B in 15 min.).

Compound 27

To a solution of **26** (23.6 mg, 3.7 μmol) in H₂O (2.0 mL), sodium periodate (62.6 mg, 293 μmol) was added and the reaction mixture stirred at room temperature for 30 minutes. Direct RP-HPLC purification, followed by lyophilization afforded pure compound **27** (17.7 mg, 78% yield). ESI⁺-MS *m/z* (Average MW) Elemental analysis calcd (%) for C₂₆₇H₄₁₆N₉₅O₇₈ [M+3H]³⁺: 2068.2, found: 2067.7; Elemental analysis calcd (%) for C₂₆₇H₄₁₇N₉₅O₇₈ [M+4H]⁴⁺: 1551.4, found: 1551.1; Elemental analysis calcd (%) for C₂₆₇H₄₁₈N₉₅O₇₈ [M+5H]⁵⁺: 1241.4, found: 1241.1. Analytical RP-HPLC: *t*_R = 8.11 min. (5–100% solv. B in 15 min.).

Compound 28

To a mixture of H₂O/CH₃CN (1:1, 1.0 mL) containing 0.09% CF₃CO₂H, **4**^[59] (7.6 mg, 6.1 μmol) and **7** (48.1 mg, 36.4 μmol) were added and the reaction heated at 37 °C for 30 minutes. RP-HPLC purification afforded, after lyophilization, pure compound **28** (34.2 mg) in 87% yield. ESI⁺-MS *m/z* (Average MW) Elemental analysis calcd (%) for C₂₇₅H₄₅₇N₁₀₃O₇₈ [M+4H]⁴⁺: 1613.6, found: 1613.5; calcd for C₂₇₅H₄₅₈N₁₀₃O₇₈ [M+5H]⁵⁺: 1291.0, found: 1291.1; Elemental analysis calcd (%) for C₂₇₅H₄₅₉N₁₀₃O₇₈ [M+6H]⁶⁺: 1076.0, found: 1076.2. Analytical RP-HPLC: *t*_R = 4.31 min. (5–100% solv. B in 15 min.).

Compound 29

Compound **29** was obtained in 73% yield (15.3 mg) by following the same procedure reported above, starting from 21.8 mg (3.4 μmol) of compound **28**. ESI⁺-MS *m/z* (Average MW) Elemental analysis calcd (%) for C₂₆₇H₄₁₆N₉₅O₇₈ [M+3H]³⁺: 2068.3, found: 2068.5; calcd for C₂₆₇H₄₁₇N₉₅O₇₈ [M+4H]⁴⁺: 1551.4, found: 1551.7; Elemental analysis calcd (%) for C₂₆₇H₄₁₈N₉₅O₇₈ [M+5H]⁵⁺: 1241.4, found: 1241.6; C₂₆₇H₄₂₃N₉₅O₇₈ [M+10H]¹⁰⁺: 621.2, found: 620.9. Analytical RP-HPLC: *t*_R = 8.08 min. (5–100% solv. B in 15 min.).

Enzyme-linked immunosorbent assay

96-well microtiter Nunc-Immuno plates (Maxi-Sorp) were coated with serial two-fold dilutions of each glycoclusters in PBS buffer pH 7.4 (from 100 μM to 3 nM, 100 μL per well,) for 1 h at 37 °C. The wells were then washed with T-PBS (3 \times 100 μL per well, PBS pH 7.4 containing 0.05% (v/v) Tween 20). This washing procedure was repeated after each incubation step. The coated microtiter plates were then blocked with BSA in PBS (3% w/v, 1 h at 37 °C, 100 μL per well). Primary mouse anti-Tn monoclonal antibody (9A7) was then added (100 μL per well) and plates were incubated for 1 h at 37 °C. The Anti-Tn antibody interaction with the coated glycoclusters was revealed by using goat anti-mouse IgG peroxidase conjugate 1:1000 (100 μL per well, incubation 1 h at 37 °C) and *o*-phenyldiamine/H₂O₂ substrate (OPD 100 μL per well). The reaction was stopped after 10 min by adding H₂SO₄ (30% v/v, 50 μL per well) and the absorbance was measured at 490 nm. Glycoclusters presenting four GlcNAc residues (**32**, **33**) were used as control for specificity. The optical density (OD at 490 nm) was plotted against the logarithm of the concentration for each glycocluster. The sigmoidal curves were fitted using Origin v6.1 software.

Acknowledgements

This work was partly supported by CNRS, Université Grenoble Alpes, the “Communauté d’agglomération Grenoble-Alpes Métropole” (Nanobio program), the French National Research Agency in the framework of the “Investissements d’avenir” program Glyco@Alps (ANR-15-IDEX-02) and Labex ARCANE (ANR-11-LABX-0003-01). O.R. acknowledges the French National Research Agency (ANR-12-JS07-0001-01 “VacSyn”) and the European Research Council Consolidator Grant “LEGO” (647938). We thank Dr R. Lo-Man for providing the anti-Tn monoclonal antibody 9A7.

Conflict of interest

The authors declare no conflict of interest.

Keywords: chemoselective ligation · heteroglycodendrimers · synthetic vaccine · TF antigen · Tn antigen

- [1] L. Cipolla, F. Peri, C. Airoldi, *Anticancer Agents Med. Chem.* **2008**, *8*, 92–121.
- [2] Z. Guo, G.-J. Boons, in *Carbohydrate-Based Vaccines and Immunotherapeutics* (Ed.: B. Wang), **2009**, pp. 1–416.
- [3] R. D. Astronomo, D. R. Burton, *Nat. Rev. Drug Discovery* **2010**, *9*, 308–324.
- [4] D. Feng, A. S. Shaikh, F. Wang, *ACS Chem. Biol.* **2016**, *11*, 850–863.
- [5] N. Gaidzik, U. Westerlind, H. Kunz, *Chem. Soc. Rev.* **2013**, *42*, 4421–4442.
- [6] E. Meezan, H. C. Wu, P. H. Black, P. W. Robbins, *Biochemistry* **1969**, *8*, 2518–2524.
- [7] S. Hakomori, *Cancer Res.* **1985**, *45*, 2405–2414.
- [8] K. O. Lloyd, *Semin. Cancer Biol.* **1991**, *2*, 421–431.
- [9] P. O. Livingston, *Immunol. Rev.* **1995**, *145*, 147–166.
- [10] M. Fukuda, *Cancer Res.* **1996**, *56*, 2237–2244.
- [11] S. Hakomori, Y. Zhang, *Chem. Biol.* **1997**, *4*, 97–104.
- [12] R. S. Bresalier, Y. Niv, J. C. Byrd, Q. Y. Duh, N. W. Toribara, R. W. Rockwell, R. Dahiya, Y. S. Kim, *J. Clin. Invest.* **1991**, *87*, 1037–1045.
- [13] J. L. Werther, M. Matematsu, R. Klein, M. Kurihara, K. Kumagai, P. Llorens, N. J. Guidugli, C. Bodian, D. Pertsemliadis, T. Yamachika, et al., *Int. J. Cancer* **1996**, *69*, 193–199.
- [14] P. O. Livingston, G. Y. Wong, S. Adluri, Y. Tao, M. Padavan, R. Parente, C. Hanlon, M. J. Calves, F. Helling, G. Ritter, *J. Clin. Oncol.* **1994**, *12*, 1036–1044.
- [15] D. E. Speiser, R. Miranda, A. Zakarian, M. F. Bachmann, K. Mckall-Faienza, B. Odermatt, D. Hanahan, R. M. Zinkernagel, P. S. Ohashi, *J. Exp. Med.* **1997**, *186*, 645–653.
- [16] R. Kennedy, E. Celis, *Immunol. Rev.* **2008**, *222*, 129–144.
- [17] R. N. Germain, D. H. Margulies, *Annu. Rev. Immunol.* **1993**, *11*, 403–450.
- [18] J. S. Haurum, G. Arsequell, A. C. Lellouch, S. Y. C. Wong, R. A. Dwek, A. J. McMichael, T. Elliott, *J. Exp. Med.* **1994**, *180*, 739–744.
- [19] T. Dudler, F. Altmann, J. M. Carballido, K. Blaser, *Eur. J. Immunol.* **1995**, *25*, 538–542.
- [20] S. J. Danishefsky, J. R. Allen, *Angew. Chem. Int. Ed.* **2000**, *39*, 836–863; *Angew. Chem.* **2000**, *112*, 882–912.
- [21] B. Temizoz, E. Kuroda, K. J. Ishii, *Int. Immunol.* **2016**, *28*, 329–338.
- [22] E. M. S. Fernandez, C. D. Navo, N. Martinez-Saez, R. Goncalves-Pereira, V. J. Somovilla, A. Avenoza, J. H. Busto, G. J. L. Bernardes, G. Jimenez-Oses, F. Corzana, et al., *Org. Lett.* **2016**, *18*, 3890–3893.
- [23] V. Rojas-Ocáriz, I. Companon, C. Aydllo, J. Castro-Lopez, J. Jimenez-Barbero, R. Hurtado-Guerrero, A. Avenoza, M. M. Zurbano, J. M. Peregrina, J. H. Busto, et al., *J. Org. Chem.* **2016**, *81*, 5929–5941.
- [24] N. Martínez-Sáez, J. Castro-Lopez, J. Valero-Gonzalez, D. Madariaga, I. Companon, V. J. Somovilla, M. Salvado, J. L. Asensio, J. Jimenez-Barbero, A. Avenoza, et al., *Angew. Chem. Int. Ed.* **2015**, *54*, 9830–9834; *Angew. Chem.* **2015**, *127*, 9968–9972.
- [25] D. Madariaga, N. Martinez-Saez, V. J. Somovilla, H. Coelho, J. Valero-Gonzalez, J. Castro-Lopez, J. L. Asensio, J. Jimenez-Barbero, J. H. Busto, A. Avenoza, et al., *ACS Chem. Biol.* **2015**, *10*, 747–756.
- [26] P. H. Seeberger, D. B. Werz, *Nature* **2007**, *446*, 1046–1051.
- [27] R. M. Wilson, S. J. Danishefsky, *J. Am. Chem. Soc.* **2013**, *135*, 14462–14472.
- [28] Y. E. C. A. Townsend, in *Comprehensive Natural Products II, Chemistry and Biology, Vol. 1* (Eds.: L. Mander, H.-W. Liu), **2010**, pp. 95–96.
- [29] N. Gaidzik, A. Kaiser, D. Kowalczyk, U. Westerlind, B. Gerlitzki, H. P. Sinn, E. Schmitt, H. Kunz, *Angew. Chem. Int. Ed.* **2011**, *50*, 9977–9981; *Angew. Chem.* **2011**, *123*, 10153–10157.
- [30] H. Cai, Z. Sun, M. Chen, Y. Zhao, H. Kunz, Y. Li, *Angew. Chem. Int. Ed.* **2014**, *53*, 1699–1703; *Angew. Chem.* **2014**, *126*, 1725–1729.
- [31] L. L. Kiessling, J. C. Grim, *Chem. Soc. Rev.* **2013**, *42*, 4476–4491.
- [32] M. Fiore, B. Thomas, G. C. Daskhan, O. Renaudet, in *Carbohydrates Chemistry: State-of-the-Art and Challenges for Drug Development*, (Ed.: L. Cipolla), **2015**, chapter 14, pp. 357–378.
- [33] B. Richichi, B. Thomas, M. Fiore, R. Bosco, H. Qureshi, C. Nativi, O. Renaudet, L. Ben Mohamed, *Angew. Chem. Int. Ed.* **2014**, *53*, 11917–11920; *Angew. Chem.* **2014**, *126*, 12111–12114.
- [34] B. Palitzsch, N. Gaidzik, N. Stergiou, S. Stahn, S. Hartmann, B. Gerlitzki, N. Teusch, P. Flemming, E. Schmitt, H. Kunz, *Angew. Chem. Int. Ed.* **2016**, *55*, 2894–2898; *Angew. Chem.* **2016**, *128*, 2944–2949.
- [35] I. Jeon, D. Lee, I. J. Krauss, S. J. Danishefsky, *J. Am. Chem. Soc.* **2009**, *131*, 14337–14344.
- [36] R. Lo-Man, S. Bay, S. Vichier-Guerre, E. Deriaud, D. Cantacuzene, C. Leclerc, *Cancer Res.* **1999**, *59*, 1520–1524.
- [37] B. Gungor, F. C. Yagci, G. Tincer, B. Bayyurt, E. Alpdundar, S. Yildiz, M. Ozcan, I. Gursel, M. Gursel, *Sci. Transl. Med.* **2014**, *6*, 235ra61/1–235ra61/12, 12.
- [38] A. Fernández-Tejada, E. K. Chea, C. George, N. V. K. Pillarsetty, J. R. Gardner, P. O. Livingston, G. Ragupathi, J. S. Lewis, D. S. Tan, D. Y. Gin, *Nat. Chem.* **2014**, *6*, 635–643.
- [39] A. Di Pasquale, S. Preiss, F. Tavares Da Silva, N. Garçon, *Vaccine* **2015**, *3*, 320–343.
- [40] T. Buskas, S. Ingale, G.-J. Boons, *Angew. Chem. Int. Ed.* **2005**, *44*, 5985–5988; *Angew. Chem.* **2005**, *117*, 6139–6142.
- [41] I. Bettahi, G. Dasgupta, O. Renaudet, A. A. Chentoufi, X. Zhang, D. Carpenter, S. Yoon, P. Dumy, L. BenMohamed, *Cancer Immunol. Immunother.* **2009**, *58*, 187–200.
- [42] S. Sarkar, S. A. Lombardo, D. N. Herner, R. S. Talan, K. A. Wall, S. J. Scheck, *J. Am. Chem. Soc.* **2010**, *132*, 17236–17246.
- [43] B. L. Wilkinson, S. Day, L. R. Malins, V. Apostolopoulos, R. J. Payne, *Angew. Chem. Int. Ed.* **2011**, *50*, 1635–1639; *Angew. Chem.* **2011**, *123*, 1673–1677.
- [44] A.-B. M. Abdel-Aal, D. El-Naggar, M. Zaman, M. Batzloff, I. Toth, *J. Med. Chem.* **2012**, *55*, 6968–6974.
- [45] X.-G. Yin, X.-Z. Chen, W.-M. Sun, X.-S. Geng, X.-K. Zhang, J. Wang, P.-P. Ji, Z.-Y. Zhou, D. J. Baek, G.-F. Yang, et al., *Org. Lett.* **2017**, *19*, 456–459.
- [46] S. Ingale, M. A. Wolfert, J. Gaekwad, T. Buskas, G.-J. Boons, *Nat. Chem. Biol.* **2007**, *3*, 663–667.
- [47] H. Cai, F. Degliangeli, B. Palitzsch, B. Gerlitzki, H. Kunz, E. Schmitt, R. Fiammengo, U. Westerlind, *Bioorg. Med. Chem.* **2016**, *24*, 1132–1135.
- [48] M. Glaffig, B. Palitzsch, S. Hartmann, C. Schüll, L. Nuhn, B. Gerlitzki, E. Schmitt, H. Frey, H. Kunz, *Chem. Eur. J.* **2014**, *20*, 4232–4236.
- [49] D. Miles, H. Roche, M. Martin, T. J. Perren, D. A. Cameron, J. Glaspy, D. Dodwell, J. Parker, J. Mayordomo, A. Tres, et al., *Oncologist* **2011**, *16*, 1092–1100.
- [50] S. Zhang, C. Cordon-Cardo, H. S. Zhang, V. E. Reuter, S. Adluri, W. B. Hamilton, K. O. Lloyd, P. O. Livingston, *Int. J. Cancer* **1997**, *73*, 42–49.
- [51] S. Zhang, H. S. Zhang, C. Cordon-Cardo, V. E. Reuter, A. K. Singhal, K. O. Lloyd, P. O. Livingston, *Int. J. Cancer* **1997**, *73*, 50–56.
- [52] S. Zhang, H. S. Zhang, V. E. Reuter, S. F. Slovin, H. I. Scher, P. O. Livingston, *Clin. Cancer Res.* **1998**, *4*, 295–302.
- [53] P. Livingston, *Clin. Cancer Res.* **2001**, *7*, 1837–1838.
- [54] D. H. Dube, C. R. Bertozzi, *Nat. Rev. Drug Discovery* **2005**, *4*, 477–488.
- [55] C. Ortiz Mellet, J.-F. Nierengarten, J. M. Garcia Fernandez, *J. Mater. Chem. B* **2017**, *5*, 6428–6436.
- [56] G. Ragupathi, D. M. Coltart, L. J. Williams, F. Koide, E. Kagan, J. Allen, C. Harris, P. W. Glunz, P. O. Livingston, S. J. Danishefsky, *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 13699–13704.
- [57] J. Zhu, Q. Wan, D. Lee, G. Yang, M. K. Spassova, O. Ouerfelli, G. Ragupathi, P. Damani, P. O. Livingston, S. J. Danishefsky, *J. Am. Chem. Soc.* **2009**, *131*, 9298–9303.
- [58] C. Pett, H. Cai, J. Liu, B. Palitzsch, M. Schorlemer, S. Hartmann, N. Stergiou, M. Lu, H. Kunz, E. Schmitt, U. Westerlind, *Chem. Eur. J.* **2017**, *23*, 4018.
- [59] C. Pifferi, N. Berthet, O. Renaudet, *Biomater. Sci.* **2017**, *5*, 953–965.
- [60] S. Grigalevicius, S. Chierici, O. Renaudet, R. Lo-Man, E. Deriaud, C. Leclerc, P. Dumy, *Bioconjugate Chem.* **2005**, *16*, 1149–1159.
- [61] O. Renaudet, L. BenMohamed, G. Dasgupta, I. Bettahi, P. Dumy, *Chem-MedChem* **2008**, *3*, 737–741.
- [62] O. Renaudet, G. Dasgupta, I. Bettahi, A. Shi, A. B. Nesburn, P. Dumy, L. BenMohamed, *PLoS One* **2010**, *5*, e11216.

- [63] J. L. Jiménez Blanco, C. Ortiz Mellet, J. M. García Fernández, *Chem. Soc. Rev.* **2013**, *42*, 4518–4531.
- [64] M. I. García-Moreno, F. Ortega-Caballero, R. Rísquez-Cuadro, C. Ortiz Mellet, J. M. García Fernández, *Chem. Eur. J.* **2017**, *23*, 6295–6304.
- [65] M. Galibert, O. Renaudet, P. Dumy, D. Boturyn, *Angew. Chem. Int. Ed.* **2011**, *50*, 1901–1904; *Angew. Chem.* **2011**, *123*, 1941–1944.
- [66] N. Berthet, B. Thomas, I. Bossu, E. Dufour, E. Gillon, J. Garcia, N. Spinelli, A. Imbert, P. Dumy, O. Renaudet, *Bioconjugate Chem.* **2013**, *24*, 1598–1611.
- [67] B. Thomas, M. Fiore, G. C. Daskhan, N. Spinelli, O. Renaudet, *Chem. Commun.* **2015**, *51*, 5436–5439.
- [68] O. Renaudet, P. Dumy, *Org. Biomol. Chem.* **2006**, *4*, 2628–2636.
- [69] E. D. Goddard-Borger, R. V. Stick, *Org. Lett.* **2007**, *9*, 3797–3800.
- [70] B. Thomas, C. Pifferi, G. C. Daskhan, M. Fiore, N. Berthet, O. Renaudet, *Org. Biomol. Chem.* **2015**, *13*, 11529–11538.
- [71] S. Foillard, M. Ohsten Rasmussen, J. Razkin, D. Boturyn, P. Dumy, *J. Org. Chem.* **2008**, *73*, 983–991.
- [72] M. Lelle, K. Peneva, *Amino Acids* **2014**, *46*, 1243–1251.
- [73] O. El-Mahdi, O. Melnyk, *Bioconjugate Chem.* **2013**, *24*, 735–765.
- [74] C. Byrne, P. A. McEwan, J. Emsley, P. M. Fischer, W.-C. Chan, *Chem. Commun.* **2011**, *47*, 2589–2591.
- [75] Y. Singh, O. Renaudet, E. Defrancq, P. Dumy, *Org. Lett.* **2005**, *7*, 1359–1362.
- [76] V. Hong, S. I. Presolski, C. Ma, M. G. Finn, *Angew. Chem. Int. Ed.* **2009**, *48*, 9879–9883; *Angew. Chem.* **2009**, *121*, 10063–10067.
- [77] L. L. Kiessling, J. E. Gestwicki, L. E. Strong, *Angew. Chem. Int. Ed.* **2006**, *45*, 2348–2368; *Angew. Chem.* **2006**, *118*, 2408–2429.
- [78] D. Mazal, R. Lo-Man, S. Bay, O. Pritsch, E. Dériaud, C. Ganneau, A. Me-deiros, L. Ubbilos, G. Obal, N. Berois, et al., *Cancer Immunol. Immunother.* **2013**, *62*, 1107–1122.
- [79] L. Nagel, C. Budke, R. S. Erdmann, A. Dreyer, H. Wennemers, T. Koop, N. Sewald, *Chem. Eur. J.* **2012**, *18*, 12783–12793.

Manuscript received: June 12, 2017

Accepted manuscript online: August 28, 2017

Version of record online: October 25, 2017